Optimising Outcomes in NSCLC: ctDNA Genotyping and Ultra-Fast NGS for Timely and Comprehensive Biomarker Testing at Diagnosis and at Progression

Wednesday, November 20, 2024

9:00 AM – 9:50 AM PST

Location: 217 - 219, Level 2

Corporate Workshop Speaker(s)

BM

Barbara Melosky, MD

Clinical Professor of Medicine
University of British Columbia
BS

Brandon Sheffield, MD

Diagnostic and Molecular Pathologist
William Osler Health System
PC

Parneet M. Cheema, MD, FRCP

Medical Director, Oncology
William Osler Health System

This programme explores the use of in-house ultra-fast next-generation sequencing (NGS) for diagnosing non-small cell lung cancer (NSCLC) and its potential impact on patient outcomes from the pathologist and oncologist perspectives. Emphasising timely and comprehensive testing for treatment decisions, it discusses the rationale for ultra-fast NGS implementation. Considerations for establishing the protocol, including a multidisciplinary approach, are outlined. It will examine circulating tumour DNA (ctDNA) genotyping in metastatic NSCLC at diagnosis and progression, comparing it with tissue biopsy. Guideline recommendations, current genotyping applications, and pre-analytical challenges are reviewed. Case studies highlight successful ctDNA testing with limited tissue availability.